Rodent models of streptozotocin-induced diabetic nephropathy (methods in renal research)

Nephrology

Volumn 12, Issue 3, 2007, Pages 261-266

  Tesch, Greg H ^a,c   Allen, Terri J ^b  

^a MONASH UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c MONASH MEDICAL CENTRE   (Australia)

Author keywords

Diabetic nephropathy; Mouse; Rat; Streptozotocin

Indexed keywords

STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE MODEL; DNA MODIFICATION; HISTOLOGY; HYPERTENSION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; STREPTOZOCIN DIABETES; UNINEPHRECTOMY; VALIDATION STUDY;

ALBUMINURIA; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; INSULIN-SECRETING CELLS; KIDNEY; MICE; RATS; STREPTOZOCIN;

EID: 34248216953     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2007.00796.x     Document Type: Article

References (23)

1. Lee TN, Alborn WE, Knierman MD, Konrad RJ. The diabetogenic antibiotic streptozotocin modifies the tryptic digest pattern for peptides of the enzyme O-GlcNAc-selective N-acetyl-beta-d-glucosaminidase that contain amino acid residues essential for enzymatic activity. Biochem. Pharmacol. 2006 72 : 710 18.
2. Candido R, Jandeleit-Dahm KA, Cao Z et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002 106 : 246 53.
3. Gurley SB, Clare SE, Snow KP, Hu A, Meyer TW, Coffman TM. Impact of genetic background on nephropathy in diabetic mice. Am. J. Physiol. Renal Physiol. 2006 290 : F214 22.
4. Tay YC, Wang Y, Kairaitis L, Rangan GK, Zhang C, Harris D. Can murine diabetic nephropathy be separated from superimposed acute renal failure? Kidney Int. 2005 68 : 391 8.
5. Kraynak AR, Storer RD, Jensen RD et al. Extent and persistence of streptozotocin-induced DNA damage and cell proliferation in rat kidney as determined by in vivo alkaline elution and BrdUrd labeling assays. Toxicol. Appl. Pharmacol. 1995 135 : 279 86.
6. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollins BJ, Tesch GH. Monocyte chemoattractant protein-1 promotes diabetic renal injury in streptozotocin-treated mice. Kidney Int. 2006 69 : 73 80.
7. Ma G, Allen TJ, Cooper ME, Cao Z. Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes. Kidney Int. 2004 66 : 1090 98.
8. Cooper ME, Allen TJ, Macmillan P, Bach L, Jerums G, Doyle AE. Genetic hypertension accelerates nephropathy in the streptozotocin diabetic rat. Am. J. Hypertens. 1988 1 : 5 10.
9. Davis BJ, Johnston CI, Burrell LM et al. Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia 2003 46 : 961 71.
10. Allen TJ, Cao Z, Yousef S, Hulthen UL, Cooper ME. The role of angiotensin II and bradykinin in experimental diabetic nephropathy: Functional and structural studies. Diabetes 1997 46 : 1612 18.
11. Kang MJ, Ingram A, Ly H, Thai K, Scholey JW. Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression. Kidney Int. 2000 58 : 1677 85.
12. Utimura R, Fujihara CK, Mattar AL, Malheiros DM, Noronha IL, Zatz R. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int. 2003 63 : 209 16.
13. Lassila M, Seah KK, Allen TJ et al. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: Role of advanced glycation end products. J. Am. Soc. Nephrol. 2004 15 : 2125 38.
14. Keppler A, Gretz N, Schmidt R et al. Plasma creatinine determination in mice and rats: An enzymatic method compares favorably with a high-performance liquid chromatography assay. Kidney Int. 2007 71 : 74 8.
15. Qi Z, Whitt I, Mehta A et al. Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am. J. Physiol. Renal Physiol. 2004 286 : F590 96.
16. Allen TJ, Cooper ME, O'Brien RC, Bach LA, Jackson B, Jerums G. Glomerular filtration rate in streptozocin-induced diabetic rats. Role of exchangeable sodium, vasoactive hormones, and insulin therapy. Diabetes 1990 39 : 1182 90.
17. Chow FY, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in streptozotocin-induced diabetic nephropathy: Potential role in renal fibrosis. Nephrol. Dial. Transplant. 2004 19 : 2987 96.
18. Cooper ME, Allen TJ, Macmillan PA, Clarke BE, Jerums G, Doyle AE. Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat. Diabetologia 1989 32 : 326 8.
19. Qi Z, Fujita H, Jin J et al. Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 2005 54 : 2628 37.
20. Calkin AC, Giunti S, Jandeleit-Dahm KA, Allen TJ, Cooper ME, Thomas MC. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol. Dial. Transplant. 2006 21 : 2399 405.
21. Lassila M, Jandeleit-Dahm KA, Seah KK et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J. Am. Soc. Nephrol. 2005 16 : 363 73.
22. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int. 1998 54 : 343 52.
23. Hartner A, Cordasic N, Klanke B, Wittmann M, Veelken R, Hilgers KF. Renal injury in streptozotocin-diabetic Ren2-transgenic rats is mainly dependent on hypertension, not on diabetes. Am. J. Physiol. Renal Physiol. 2007 292 : F820 27.